SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

被引：0
|
作者：
Javier Escalada
机构：
[1] Clínica Universidad de Navarra,Department of Endocrinology and Nutrition
[2] Instituto de Salud Carlos III,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Type 2 diabetes; SGLT2 inhibitors; Cardiorenal; Cardiovascular disease; Kidney disease; Heart failure; Morbidity; Mortality; Chronic kidney disease; Cardiorenal continuum;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 3
页数：2
相关论文
共 50 条
  • [31] Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
    Scheen, Andre J.
    DIABETES EPIDEMIOLOGY AND MANAGEMENT, 2024, 13
  • [32] SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
    Packer, Milton
    DIABETES CARE, 2020, 43 (03) : 508 - 511
  • [33] Cardiorenal protection of SGLT2 inhibitors- Perspectives from metabolic reprogramming
    Gao, Yue-Ming
    Feng, Song-Tao
    Wen, Yi
    Wang, Tao-Tao Tang Bin
    Liu, Bi-Cheng
    EBIOMEDICINE, 2022, 83
  • [34] Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
    Verma, Subodh
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (02): : 180 - 182
  • [35] Sodium Glucose Cotransporter 2 (SGLT2) Inhibition with Empagliflozin (EMPA) Reduces Microalbuminuria in Patients with Type 2 Diabetes (T2D)
    Cherney, David
    Von Eynatten, Maximilian
    Lund, Soeren
    Kaspers, Stefan
    Crowe, Suzanne
    Woerle, Hans J.
    Hach, Thomas
    DIABETES, 2014, 63 : A293 - A293
  • [36] SGLT2 Inhibitors and Safety in Older Patients
    Pollack, Rena
    Cahn, Avivit
    HEART FAILURE CLINICS, 2022, 18 (04) : 635 - 643
  • [37] Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of dementia in people with type 2 diabetes (T2D): A populationbased cohort study
    Tang, Huilin
    Shaaban, C. Elizabeth
    Wu, Yonghui
    Magoc, Tanja
    Donahoo, William Troy
    DeKosky, Steven
    Bian, Jiang
    Guo, Serena Jingchuan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 376 - 376
  • [38] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [39] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [40] Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis
    Tian, Qi
    Guo, Keyu
    Deng, Jiayi
    Zhong, Yanjun
    Yang, Lin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (02) : 540 - 547
12345